(Q36580997)

15 August 2017

1 reference

title

Early intervention to achieve optimal outcomes in type 2 diabetes: a case presentation (English)

1 reference

15 August 2017

1 reference

Stephen A Brunton

1

1 reference

15 August 2017

Stephen N Davis

series ordinal

2

1 reference

15 August 2017

Susan M Renda

series ordinal

3

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

8 Suppl 2

1 reference

15 August 2017

page(s)

S6-S18

1 reference

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Beta-cell rejuvenation with thiazolidinediones

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Hypertension management in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Dyslipidemia management in adults with diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

The underuse of insulin therapy in North America

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Insulin treatment reverses the insulin resistance of type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1098-3597%2806%2980011-6

7 January 2021

10.1016/S1098-3597(06)80011-6

Identifiers

DOI

1 reference

15 August 2017

1 reference